Comparative Pharmacology
Head-to-head clinical analysis: CORTENEMA versus HYDELTRA TBA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTENEMA versus HYDELTRA TBA.
CORTENEMA vs HYDELTRA-TBA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to the glucocorticoid receptor, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, decrease cytokine production, and suppress inflammatory cell migration and activation in the colonic mucosa.
Prednisolone is a synthetic glucocorticoid that binds to the glucocorticoid receptor, modulating gene transcription to suppress inflammation, immune response, and adrenal function.
One enema (100 mg hydrocortisone in 60 mL) administered rectally once daily, preferably at bedtime, for 21 days or until clinical response.
20-40 mg intramuscularly every 3 weeks; for intra-articular use: 20-40 mg per large joint, 10-20 mg per medium joint, 4-10 mg per small joint.
None Documented
None Documented
1.8-3.5 hours (plasma); due to rectal administration and low systemic absorption, clinical effects persist longer than plasma levels suggest
Plasma t1/2 ~2.5-3.5 hours. Duration of adrenal suppression may persist for 24-48 hours.
Primarily hepatic metabolism with renal excretion of inactive metabolites; <5% unchanged in urine; biliary/fecal elimination of metabolites accounts for ~80%
Primarily renal (80-90% as inactive metabolites and unchanged drug). Biliary excretion accounts for <5%.
Category C
Category C
Corticosteroid
Corticosteroid